Halozyme Therapeutics, Inc.
HALO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $116 | $118 | $234 | $119 |
| Short-Term Investments | $480 | $218 | $129 | $622 |
| Receivables | $308 | $234 | $231 | $91 |
| Inventory | $142 | $128 | $100 | $54 |
| Other Curr. Assets | $39 | $49 | $45 | $40 |
| Total Curr. Assets | $1,085 | $746 | $739 | $926 |
| Property Plant & Equip (Net) | $75 | $75 | $76 | $9 |
| Goodwill | $417 | $417 | $409 | $0 |
| Intangibles | $402 | $473 | $547 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $4 | $4 | $44 | $155 |
| Other NC Assets | $81 | $18 | $27 | $14 |
| Total NC Assets | $978 | $987 | $1,102 | $178 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $2,063 | $1,733 | $1,842 | $1,104 |
| Liabilities | – | – | – | – |
| Payables | $10 | $12 | $18 | $2 |
| Short-Term Debt | $0 | $0 | $13 | $89 |
| Tax Payable | $0 | $1 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $3 | $2 |
| Other Curr. Liab. | $129 | $100 | $97 | $24 |
| Total Curr. Liab. | $139 | $112 | $131 | $117 |
| LT Debt | $1,506 | $1,499 | $1,493 | $787 |
| Deferred Rev, NC | $0 | $0 | $2 | $3 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $55 | $38 | $46 | $1 |
| Total NC Liab. | $1,561 | $1,537 | $1,541 | $790 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $1,700 | $1,649 | $1,672 | $907 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | $360 | $91 | $143 | -$59 |
| AOCI | $4 | -$9 | -$1 | -$1 |
| Other Equity | $0 | $2 | $27 | $256 |
| Total Equity | $364 | $84 | $170 | $197 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $2,063 | $1,733 | $1,842 | $1,104 |
| Net Debt | $1,390 | $1,381 | $1,272 | $758 |